Zacks Research Brokers Raise Earnings Estimates for A

Agilent Technologies, Inc. (NYSE:A) – Zacks Research increased their Q2 2026 EPS estimates for shares of Agilent Technologies in a report issued on Wednesday, December 11th. Zacks Research analyst R. Department now anticipates that the medical research company will earn $1.47 per share for the quarter, up from their previous forecast of $1.46. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.56 per share. Zacks Research also issued estimates for Agilent Technologies’ Q4 2026 earnings at $1.70 EPS and FY2027 earnings at $6.67 EPS.

Agilent Technologies (NYSE:A) last posted its earnings results on Monday, November 25th. The medical research company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.41 by $0.05. Agilent Technologies had a net margin of 19.80% and a return on equity of 25.43%. The firm had revenue of $1.70 billion during the quarter, compared to analyst estimates of $1.67 billion. During the same period in the previous year, the firm earned $1.38 EPS. The business’s quarterly revenue was up .8% on a year-over-year basis.

A number of other analysts also recently commented on A. Bank of America cut their price objective on shares of Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating for the company in a report on Friday, December 13th. Evercore ISI raised their target price on Agilent Technologies from $135.00 to $145.00 and gave the company an “in-line” rating in a report on Tuesday, October 1st. Citigroup boosted their price target on shares of Agilent Technologies from $150.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. TD Cowen upped their target price on shares of Agilent Technologies from $153.00 to $160.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Finally, Wells Fargo & Company dropped their target price on Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating on the stock in a report on Monday, December 9th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $143.62.

Agilent Technologies Stock Down 0.9 %

A stock opened at $136.46 on Monday. The stock has a market capitalization of $39.21 billion, a P/E ratio of 30.87, a P/E/G ratio of 4.48 and a beta of 1.07. Agilent Technologies has a 52 week low of $124.16 and a 52 week high of $155.35. The firm has a 50-day simple moving average of $136.47 and a 200-day simple moving average of $136.46. The company has a quick ratio of 1.58, a current ratio of 2.09 and a debt-to-equity ratio of 0.57.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. raised its holdings in Agilent Technologies by 2.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 9,910 shares of the medical research company’s stock valued at $1,285,000 after acquiring an additional 226 shares during the last quarter. Brookstone Capital Management lifted its stake in shares of Agilent Technologies by 14.9% in the 2nd quarter. Brookstone Capital Management now owns 1,698 shares of the medical research company’s stock valued at $227,000 after purchasing an additional 220 shares in the last quarter. First Citizens Bank & Trust Co. lifted its position in Agilent Technologies by 2.5% during the second quarter. First Citizens Bank & Trust Co. now owns 7,379 shares of the medical research company’s stock valued at $957,000 after buying an additional 180 shares in the last quarter. Dakota Wealth Management boosted its position in Agilent Technologies by 8.6% during the 2nd quarter. Dakota Wealth Management now owns 6,380 shares of the medical research company’s stock worth $827,000 after purchasing an additional 505 shares during the period. Finally, Fifth Third Bancorp grew its stake in shares of Agilent Technologies by 2.3% in the second quarter. Fifth Third Bancorp now owns 34,173 shares of the medical research company’s stock valued at $4,430,000 after buying an additional 756 shares in the last quarter. Institutional investors and hedge funds own 87.42% of the company’s stock.

Insider Transactions at Agilent Technologies

In other news, SVP Dominique Grau sold 9,990 shares of the business’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $145.00, for a total value of $1,448,550.00. Following the completion of the transaction, the senior vice president now directly owns 40,011 shares of the company’s stock, valued at $5,801,595. The trade was a 19.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 0.33% of the company’s stock.

Agilent Technologies Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 22nd. Investors of record on Tuesday, December 31st will be paid a $0.248 dividend. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.24. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $0.99 annualized dividend and a dividend yield of 0.73%. Agilent Technologies’s dividend payout ratio (DPR) is 22.40%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.